Colorado Public Radio13h
Allergy pen maker sues Colorado over state affordability program
Under Colorado’s affordability program any time an eligible uninsured Coloradan acquires an auto-injector from a pharmacy in ...
Zacks.com on MSN16h
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease
AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...
GlobalData on MSN19h
EMA CHMP recommends AstraZeneca’s Fasenra to treat EGPA
Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...
Amneal asks court to block Colorado's free allergy pen program
Amneal Pharmaceuticals has sued Colorado in an effort to block a state law requiring it to provide free generic EpiPens to ...
PharmiWeb1d
Fasenra recommended for approval in the EU by CHMP for the treatment of eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s Fasenra (benralizumab) ...
EuropaWire6d
FDA Approves AstraZeneca’s Fasenra for Eosinophilic Granulomatosis with Polyangiitis, Offering New Hope for Patients
AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...